Literature DB >> 25529567

A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4⁺ T-cell response.

Kasper Karlsen1, Karen Smith Korsholm, Rasmus Mortensen, Seyed Mojtaba Ghiasi, Peter Andersen, Camilla Foged, Dennis Christensen.   

Abstract

AIM: To combine the dimethyldioctadecyl ammonium/monomycoloyl glycerol (DDA/MMG) liposomal vaccine adjuvant with the Toll-like receptor (TLR) ligands poly(I:C) (TLR3), flagellin (TLR5) or CpG oligodeoxynucleotide 1826 (TLR9) and investigate their physicochemical properties as well as their CD4(+) T-cell-inducing capacity. MATERIALS &
METHODS: Formulations were investigated by dynamic light scattering and differential scanning calorimetry. Their CD4(+) T-cell induction with a tuberculosis antigen was analyzed by multiplex cytokine analysis, ELISA and intracellular cytokine staining.
RESULTS: DDA/MMG/CpG was the best combination for obtaining increased CD4(+) T-cell responses. However, coformulating CpG and DDA/MMG liposomes led to instability and the formulation was therefore optimized systematically using a design of experiment.
CONCLUSION: The nanoparticulate DDA/MMG/CpG adjuvant can be stabilized and synergistically enhances CD4(+) T-cell responses compared with DDA/MMG liposomes.

Entities:  

Keywords:  CD4+ T cells; CpG; adjuvant; cationic liposome; pattern-recognition receptors

Mesh:

Substances:

Year:  2014        PMID: 25529567     DOI: 10.2217/nnm.14.197

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  1 in total

1.  MUC1 Specific Immune Responses Enhanced by Coadministration of Liposomal DDA/MPLA and Lipoglycopeptide.

Authors:  Jing-Jing Du; Shi-Hao Zhou; Zi-Ru Cheng; Wen-Bo Xu; Ru-Yan Zhang; Long-Sheng Wang; Jun Guo
Journal:  Front Chem       Date:  2022-02-04       Impact factor: 5.221

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.